MI-EATON-VEHICLE-GROUP
Power management company Eaton today announced its Vehicle Group has developed a series of 48-volt technologies to assist its global on- and off-highway commercial vehicle customers transitioning from traditional 12- and 24-volt vehicle systems to systems that include 48-volt architecture. These 48-volt systems can power new, advanced energy-consuming components and can help reduce emissions and improve fuel economy and performance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210810005722/en/
“This development comes as global vehicle manufacturers are making decisions to adopt new technologies to meet emissions regulations,” said Ben Karrer, manager, Technology Development, Eaton’s Vehicle Group. “Of the options available, 48-volt architectures are becoming more popular because they can decrease both CO2 and NOx simultaneously, which helps both our customers and the environment.”
Most vehicles have traditionally operated with a 12-volt system, but with tightening fuel economy regulations and new, advanced power-consuming components being added, increasing power needs are driving the move toward 48-volt systems.
Reduce mechanical loads and CO2 by powering systems with 48-volt architecture
Many vehicle systems today are powered directly from mechanical power generated by the engine, which runs 12-volt systems such as air conditioning and pumps. Eaton is developing 48-volt systems that include motor generators and inverters that generate 48-volt DC power for the vehicle. Eaton also produces 48-volt DC/DC converters that step power down from 48-volt vehicle architectures to power 12- and 24-volt systems.
48-volt system can heat aftertreatment catalyst to reduce NOx emissions
Collectively, new emissions regulations will reduce tailpipe NOx limits by up to 90%, accelerating the need for global engine manufacturers to employ additional emissions reduction strategies.
Eaton’s Vehicle Group is also developing power electronics for 48-volt electric catalyst heating, which provides heat directly to the vehicle’s aftertreatment system. This active heating helps catalyst components reach efficient operating temperatures faster upon engine start and maintain those temperatures during low load operation. This will be an essential strategy for reducing emissions to the levels required by future regulations.
“Forty-eight-volt power will also be used to power systems such as HVAC and the engine cooling fan, which are traditionally run by the engine,” said Karrer. “Today’s systems are not intelligent—you can’t control when they’re on or off or adjust the levels. Converting those components to electric alternatives allows you to intelligently control them and eliminate mechanical loads.”
Electrified cooling offers multiple environmental, efficiency improvements
An electrical engine cooling fan and electric air conditioning compressor are also under development. Electrifying the cooling fan provides additional benefits, as it could be reduced in size and strategically placed within the engine bay, allowing for aerodynamic design flexibility to increase fuel economy and reduce emissions.
Supercapacitors, lead-acid batteries for 48-volt system power storage
Eaton’s Vehicle Group is developing a wide range of 48-volt energy storage solutions, including lead-acid batteries and supercapacitors.
“We’re integrating various energy storage technologies into a larger storage pack including controls, fusing, and contactors,” said Karrer. “Eaton’s Electrical Components Group is our partner for supercapacitors, and we will be working with most commercial vehicle battery manufacturers for lead-acid batteries.”
Lead-acid batteries are inexpensive compared to lithium-ion packs and offer a safe and more efficient solution, with a longer lifespan when compared to existing lead-acid battery applications.
Supercapacitors are able to quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don’t retain high levels of energy in comparison or require a liquid cooling system, and they have a longer cycle life.
This suite of technologies is an example of how Eaton is working to achieve its 2030 Sustainability Targets , which include reducing the carbon emissions from our operations by half and lowering product and supply chain emissions. Learn more about our commitment to improving the quality of life and the environment.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005722/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom